Welcome to our dedicated page for Oncotelic Therapeutics SEC filings (Ticker: OTLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech 10-K often feels like deciphering lab notes. Oncotelic Therapeutics’ disclosures stack clinical-trial outcomes, milestone payments, and complex licensing terms on top of GAAP footnotes. Finding the real cash runway or the latest Phase 2 safety update can be a day’s work. Stock Titan’s AI trims that to minutes by converting every filing into a concise brief with risk flags and plain-English context.
As soon as EDGAR releases a document, our feed delivers Oncotelic Therapeutics Form 4 insider transactions real-time, links them to related 8-K announcements, and adds searchable annotations. You’ll see the entire stack—10-K, 10-Q, 8-K, S-1, DEF 14A—mapped to the business questions professionals ask, all backed by AI-powered summaries and real-time alerts.
Not sure where to begin? The quick links below match the exact questions investors type into Google and AI chatbots:
- Oncotelic Therapeutics insider trading Form 4 transactions
- Oncotelic Therapeutics quarterly earnings report 10-Q filing
- Oncotelic Therapeutics SEC filings explained simply
- Oncotelic Therapeutics earnings report filing analysis
- understanding Oncotelic Therapeutics SEC documents with AI
- Oncotelic Therapeutics executive stock transactions Form 4
- Oncotelic Therapeutics annual report 10-K simplified
- Oncotelic Therapeutics proxy statement executive compensation
- Oncotelic Therapeutics 8-K material events explained
Whether you monitor trial milestones, compare quarter-over-quarter R&D spend, or track executive trades ahead of pivotal readouts, Stock Titan’s AI surfaces the insights that matter—no PhD in oncology or accounting required.
Oncotelic Therapeutics, Inc. reported no revenue for the three and nine months ended September 30, 2025 and continued to operate at a loss. Net loss attributable to the company was $1.05 million for the quarter, improving from $3.30 million a year earlier, and $1.07 million for the nine‑month period versus $3.92 million in 2024. Operating expenses fell sharply year over year due to the absence of a prior $3.2 million goodwill impairment.
Cash and restricted cash totaled $429,000 at September 30, 2025, while current liabilities were $20.1 million, including $10.3 million of convertible and short‑term debt and $3.5 million of related‑party debt. Management discloses a substantial doubt about the company’s ability to continue as a going concern, citing cumulative losses of about $39.1 million, negative working capital of roughly $18.5 million, and negative operating cash flow. The company is relying on convertible notes, short‑term related‑party loans, and equity purchase agreements with Peak One and Mast Hill, while its 45% stake in JV partner GMP Bio is carried at $22.65 million based on a Level 3 fair value election.
Oncotelic Therapeutics, Inc. filed a Form 12b-25, notifying a late Form 10-Q for the quarter ended September 30, 2025.
The company says it was unable to compile the necessary financial information to complete the filing without unreasonable effort or expense and expects to file within the permitted extension period. The notification lists Amit Shah, Chief Financial Officer, as the signatory and contact.
Oncotelic Therapeutics (OTLC) furnished an investor presentation given by CEO Dr. Vuong Trieu at LD Micro in San Diego on October 21, 2025. The presentation, filed as Exhibit 99.1, includes forward-looking statements covering areas such as JV plans (including a potential IPO), clinical development timing and data reporting, regulatory approvals, the company’s nanoparticle platform, a planned DAO-based company, pet and animal health initiatives, and token-related registrations and tradability.
The materials are furnished under Item 8.01 and are not deemed “filed,” which limits their incorporation into other SEC filings.
FAQ
What is the current stock price of Oncotelic Therapeutics (OTLC)?
What is the market cap of Oncotelic Therapeutics (OTLC)?
